PainChek

PainChek Altman Z-Score

The Altman Z-Score of PainChek (PCK.AX) as of Oct 27, 2026 is -15.00. In the previous year, Altman Z-Score was -48.13 — a change of -68.82% (higher).

Altman Z-Score

-15.00

YoY

-68.82%

Last updated:

Altman Z-Score of PainChek is 2026 -15.00 . Altman Z-Score of PainChek was 2025 -48.13 . It decreases by -68.82% higher compared to the previous year.

The PainChek Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2019
25.74 AUD
Jan 1, 2020
-4.61 AUD
Jan 1, 2021
-0.87 AUD
Jan 1, 2022
-0.93 AUD
Jan 1, 2023
-24.25 AUD
Jan 1, 2024
-18.76 AUD
Jan 1, 2025
-48.13 AUD
Jan 1, 2026
-15.00 AUD
The PainChek Altman Z-Score history
YEARAltman Z-ScoreYoY
-15.00-68.82%
-48.13+156.59%
-18.76-22.66%
-24.25+2,497.41%
-0.93+7.48%
-0.87-81.18%
-4.61-117.93%
25.74-29.89%
36.71-59.38%
90.38-170.15%
-128.85-736.09%
20.26-84.01%
126.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PainChek Stock analysis

What does PainChek do? PainChek Ltd. develops and commercializes mobile medical device applications, focusing on pain assessment for individuals unable to communicate with carers. The PainChek Universal combines the PainChek Application with the numerical rating scale (NRS), using artificial intelligence and facial recognition to detect pain in non-verbal patients. It provides a point-of-care solution that offers objectivity and consistency in pain assessments, supporting both non-verbal and self-reporting individuals through integrated tools. Healthcare providers and care facilities purchase PainChek Universal to enhance pain management protocols for patients with communication difficulties. The PainChek Application utilizes artificial intelligence and facial recognition technology to assess pain without relying on patient self-reporting, making it suitable for those with cognitive or physical impairments. PainChek Universal integrates the NRS for patients who can self-report, ensuring a comprehensive approach to pain evaluation across varying patient capabilities. This dual functionality allows healthcare professionals to apply consistent assessment standards regardless of a patient's ability to communicate. PainChek Ltd. generates revenue through the commercialization of its mobile medical device applications, specifically targeting healthcare providers and care facilities that require standardized pain assessment tools. The company’s products are designed to address the needs of patients who cannot communicate pain, thereby filling a critical gap in healthcare services. By offering a unified solution that combines AI-driven detection with traditional rating scales, PainChek Universal meets the demands of modern healthcare environments seeking objective and reliable pain management solutions. PainChek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PainChek stock

Altman Z-Score of PainChek is -15.00 in 2026.

On Eulerpool you can find the complete historical development of Altman Z-Score PainChek since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — PainChek

All Key Metrics — PainChek